Inhibikase Therapeutics(IKT) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

INHIBIKASE THERAPEUTICS Earnings Preview: Recent $IKT Insider Trading, Hedge Fund Activity, and More
Quiver QuantitativeMar 23 17:06 ET
Inhibikase Therapeutics Completes Merger With CorHepta Pharmaceuticals
TipRanksFeb 24 08:28 ET
Inhibikase Announces Expansion of Senior Leadership Team
GlobeNewswireFeb 24 08:00 ET
Press Release: Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company's Growth
Dow JonesFeb 18 08:00 ET
Express News | Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth
ReutersFeb 18 08:00 ET
This PPG Industries Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
BenzingaFeb 12 09:29 ET

Comments

Trytosaveabit

Jan 30 06:08

update

$Inhibikase Therapeutics (IKT.US)$ Reuters
4 mins ago
Inhibikase Therapeutics Inc - 201 Trial Met Primary Endpoint of Safety and Tolerability!
Inhibikase Therapeutics Inc - Risvodetinib Treatment Did Not Show Improvement in Top Hierarchical Efficacy Measure

2

Jaguar8

Dec 16, 2024 10:58

🔶December 2024 Upcoming Catalysts. Save it. In alphabetical order

$ABVC BioPharma (ABVC.US)$ - Progress continues in our ADHD program with Phase IIb trials at multiple prominent sites. We aim to have an interim report by Q4 2024. ABV-1601 for MDD in cancer patients has completed Phase I study preparation, including the Site Initiation Visit (SIV). The study is set to initiate by the end of 2024.
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...

28

9

7

Jaguar8

Nov 14, 2024 21:38

NEWS ER

$Inhibikase Therapeutics (IKT.US)$
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
Positive
Secured significant financing of up to $275 million, including $110 million immediate private placement
Received FDA Study May Proceed letter for IkT-001Pro PAH trial
High trial completion rate with 120 of 126 patients completing the Phase 2 201 Trial
Negative
Increased net loss to $5.8 million in Q3 2024 from $4.6 million in Q3 2023
R&D expenses incr...

Jaguar8

Oct 29, 2024 09:18

Put on list Multiple 13Gs since last week till today. Likely a good PR coming up. Low float

$Inhibikase Therapeutics (IKT.US)$

2

Jaguar8

Oct 29, 2024 09:17

NEWS 13Gs

$Inhibikase Therapeutics (IKT.US)$
Inhibikase Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-SP IKT HOLDINGS LLC(8.69%),SP Soleus Holdings LLC(8.69%)
Inhibikase Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Soleus Private Equity Fund III, L.P.(9.99%),Soleus Private Equity GP III, LLC(9.99%), etc.

IKT Inhibikase Therapeutics

Trade Overview

Capital Trend

News

Comments

Market Insights